Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 6/20 | 0.61 |
| ▸ | CCND1 | P24385 | 6/20 | 0.61 |
| ▸ | OPA1 | O60313 | 1/20 | 0.58 |
| ▸ | EIF5B | O60841 | 1/20 | 0.58 |
| ▸ | MET | P08581 | 1/20 | 0.58 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.58 |
| ▸ | PRKACA | P17612 | 7/20 | 0.56 |
| ▸ | PRKACG | P22612 | 7/20 | 0.56 |
| ▸ | PRKACB | P22694 | 7/20 | 0.56 |
| ▸ | CAMK2D | Q13557 | 6/20 | 0.56 |
| ▸ | PRKCA | P17252 | 5/20 | 0.56 |
| ▸ | PRKCH | P24723 | 5/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.56 |
| ▸ | PRKCB | P05771 | 4/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.56 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.56 |
| ▸ | PRKCG | P05129 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329959 | 0.97 | CDK4 (0.60) | CDK4CCND1OPA1EIF5BMET | |
| SCHEMBL2343710 | 0.93 | CDK4 (0.63) | CDK4CCND1OPA1EIF5BMET | |
| SCHEMBL2881681 | 0.93 | CDK4 (0.54) | CDK4CCND1OPA1EIF5BMET | |
| SCHEMBL3047624 | 0.88 | OPA1 (0.51) | CDK4CCND1OPA1EIF5BMET | |
| SCHEMBL6327465 | 0.88 | CDK4 (0.56) | CDK4CCND1OPA1EIF5BMET | |
| SCHEMBL6326531 | 0.88 | CDK4 (0.56) | CDK4CCND1OPA1EIF5BMET | |
| SCHEMBL6332262 | 0.88 | CDK4 (0.68) | CDK4CCND1OPA1EIF5BMET | |
| SCHEMBL1395823 | 0.88 | CAMK2D (0.56) | CDK4CCND1OPA1EIF5BMET | |
| SCHEMBL6325214 | 0.87 | SIRT2 (0.60) | CDK4CCND1OPA1EIF5BMET | |
| SCHEMBL6325335 | 0.87 | OPA1 (0.48) | CDK4CCND1OPA1EIF5BMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000005-B2 | Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same | ARQULE, INC. (US) | 2015-04-07 | — | — | US | claimed |
| EP-2841069-A1 | HIGHLY PURE PYRROLOQUINOLINYL-PYRROLE-2,5-DIONE AND PYRROLOQUINOLINYL-PYRROLIDINE-2,5-DIONE AND METHODS OF PREPARING SAME | ARQULE, INC. (US) | 2015-03-04 | — | — | EP | claimed |
| WO-2013162714-A1 | HIGHLY PURE PYRROLOQUINOLINYL-PYRROLE-2,5-DIONE AND PYRROLOQUINOLINYL-PYRROLIDINE-2,5-DIONE AND METHODS OF PREPARING SAME | ARQULE, INC. (US) | 2013-10-31 | — | — | WO | claimed |
| US-20130281699-A1 | Highly Pure Pyrroloquinolinyl-Pyrrole-2,5-Dione and Pyrroloquinolinyl-Pyrrolidine-2,5-Dione and Methods of Preparing Same | ARQULE, INC. (US) | 2013-10-24 | — | — | US | claimed |
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9499540-B2 | Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same | ARQULE, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499540-B2 | Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same | ARQULE, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2010093789-A2 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20060223760-A1 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. | 2006-10-05 | — | — | US | disclosed |
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281699-A1 | Highly Pure Pyrroloquinolinyl-Pyrrole-2,5-Dione and Pyrroloquinolinyl-Pyrrolidine-2,5-Dione and Methods of Preparing Same | DHPS, QDPR, IDO1 | CDK4 705/4885CCND1 1533/4885OPA1 100/4885 |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | MKI67, NUP205, TP53 | CDK4 41/4885CCND1 253/4885OPA1 88/4885 |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | PDCD5, TP53, NUP205 | CDK4 73/4885CCND1 327/4885OPA1 27/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | CDK4 5/4885CCND1 70/4885OPA1 1798/4885 |
| US-20060223760-A1 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | MCL1, BRCA1, IDO1 | CDK4 33/4885CCND1 42/4885OPA1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.